流动资产 更改
Agenus USD 133.44M 514K 2025-12
Alaunos Therapeutics USD 1.99M 697K 2025-12
Amgen USD 31.48B 2.42B 2026-03
Anika Therapeutics USD 93.56M 9.8M 2026-03
Arrowhead Research USD 1.17B 223.75M 2025-12
AstraZeneca USD 29.61B 890M 2026-03
Bristol-Myers Squibb USD 27.21B 2.18B 2026-03
Gilead Sciences USD 19.89B 1.05B 2025-12
GlaxoSmithKline GBP 17.76B 251M 2026-03
Heron Therapeutics USD 238.07M 8.67M 2025-12
Incyte USD 5.48B 460.36M 2026-03
Intrexon USD 23.72M 45.04M 2024-06
Karyopharm Therapeutics USD 103.15M 13.4M 2025-12
Ligand Pharmaceuticals USD 832.27M 78.35M 2025-12
MacroGenics USD 219.94M 12.15M 2025-12
MannKind USD 291.58M 67.26M 2025-12
Merck USD 35.02B 8.5B 2026-03
Novartis USD 26.61B 3.85B 2026-03
Rigel Pharmaceuticals USD 214.93M 39.53M 2025-09
Roche Holding CHF 38.73B 3.03B 2025-12
Sangamo BioSciences USD 49.89M 12.3M 2025-06
Thermo Fisher Scientific USD 22.32B 6.39B 2026-03
Veracyte USD 488.38M 39.15M 2025-12
Xencor USD 599.82M 81.38M 2025-12